Fortress Biotech Inc (FBIO)

Dec 17, 2024

Fortress Biotech subsidiary gains FDA approval for cSCC therapy - Investing.com

Dec 17, 2024

Dec 17, 2024

Fortress Biotech subsidiary gains FDA approval for cSCC therapy By Investing.com - Investing.com UK

Dec 17, 2024

Dec 14, 2024

Objective long/short (FBIOP) Report - Stock Traders Daily

Dec 14, 2024

Dec 13, 2024

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewswire

Dec 13, 2024

Dec 13, 2024

Checkpoint Therapeutics Secures First FDA Approval for Novel Cancer Drug UNLOXCYT in $1B+ Market - StockTitan

Dec 13, 2024

Dec 04, 2024

Fortress Biotech (FRA:CNB1) EV-to-Revenue : 0.52 (As of Dec. 04, 2024) - GuruFocus.com

Dec 04, 2024

Dec 01, 2024

Fortress Biotech (STU:CNB1) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com

Dec 01, 2024

Nov 30, 2024

Fortress Biotech (STU:CNB1) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com

Nov 30, 2024

Nov 26, 2024

Fortress Biotech, Inc. (NASDAQ:FBIO) Shares Sold by GSA Capital Partners LLP - Defense World

Nov 26, 2024

Nov 23, 2024

FBIOP.PFD (Fortress Biotech) Earnings Yield % : N/A% (As of Nov. 23, 2024) - GuruFocus.com

Nov 23, 2024

Nov 22, 2024

(FBIOP) Trading Signals - Stock Traders Daily

Nov 22, 2024

Nov 22, 2024

Fortress Biotech (FRA:CNB0.PFD) Total Liabilities : €125.98 Mil (As of Sep. 2024) - GuruFocus.com

Nov 22, 2024

Nov 21, 2024

Certain Restricted Stock Units of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-NOV-2024. - Marketscreener.com

Nov 21, 2024

Nov 21, 2024

Certain Warrants of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-NOV-2024. - Marketscreener.com

Nov 21, 2024

Nov 21, 2024

Fortress Biotech (FRA:CNB1) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024

Nov 19, 2024

Fortress Biotech price target raised to $15 from $13 at Roth MKM - TipRanks

Nov 19, 2024

Nov 18, 2024

Fortress Biotech price target lowered to $4 from $5 at Alliance Global Partners - TipRanks

Nov 18, 2024

Nov 18, 2024

Fortress Biotech price target raised to $26 from $24 at H.C. Wainwright - TipRanks

Nov 18, 2024

Nov 18, 2024

Fortress Biotech (FRA:CNB1) Total Inventories : €9.00 Mil (As of Jun. 2024) - GuruFocus.com

Nov 18, 2024

Nov 17, 2024

Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 17, 2024

Nov 15, 2024

Fortress Biotech: Q3 Earnings Snapshot - mySA

Nov 15, 2024

Nov 15, 2024

Fortress Biotech Inc. (FBIOP) Quarterly 10-Q Report - Quartzy

Nov 15, 2024

Nov 15, 2024

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - The Manila Times

Nov 15, 2024

Nov 14, 2024

Fortress Biotech’s Q3 2024 Earnings and FDA Milestone - TipRanks

Nov 14, 2024

Nov 14, 2024

Fortress Biotech Q3 2024 Earnings: EPS Loss of $0.76 Beats Estimate, Revenue of $14.63M Misses Expectations - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024

Nov 14, 2024

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire

Nov 14, 2024

Nov 14, 2024

Avenue Therapeutics Reports $3.1M Q3 Loss, Advances Key Clinical Trials Pipeline | ATXI Stock News - StockTitan

Nov 14, 2024

Nov 12, 2024

Mustang Bio gets extension for Nasdaq compliance By Investing.com - Investing.com South Africa

Nov 12, 2024

Nov 12, 2024

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire

Nov 12, 2024

Nov 12, 2024

Checkpoint Therapeutics Sets FDA Review Date, Secures $9.2M Funding Boost Amid Q3 Loss | FBIO Stock News - StockTitan

Nov 12, 2024

Nov 12, 2024

Journey Medical's Mixed Q3: FDA Win for Rosacea Drug Despite Revenue Dip | FBIO Stock News - StockTitan

Nov 12, 2024

Nov 12, 2024

Mustang Bio gets extension for Nasdaq compliance - Investing.com

Nov 12, 2024

Nov 12, 2024

Mustang Bio Receives Positive Listing Determination from Nasdaq - The Manila Times

Nov 12, 2024

Nov 12, 2024

Mustang Bio Secures Critical Nasdaq Extension, Faces January 2025 Deadline for $1 Compliance | MBIO Stock News - StockTitan

Nov 12, 2024

Nov 12, 2024

Where are the Opportunities in (FBIOP) - Stock Traders Daily

Nov 12, 2024

Nov 07, 2024

Mustang Bio gains FDA Orphan Drug Status for glioma treatment - Investing.com India

Nov 07, 2024

Nov 07, 2024

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for - GlobeNewswire

Nov 07, 2024

Nov 07, 2024

Mustang Bio gains FDA Orphan Drug Status for glioma treatment By Investing.com - Investing.com UK

Nov 07, 2024

Nov 04, 2024

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea - GlobeNewswire

Nov 04, 2024

Nov 01, 2024

How To Trade (FBIOP) - Stock Traders Daily

Nov 01, 2024

Oct 31, 2024

Fortress Biotech Insiders Placed Bullish Bets Worth US$4.49m - Yahoo Finance

Oct 31, 2024

Oct 30, 2024

Biotech Stocks Facing FDA Decision In November 2024 - RTTNews

Oct 30, 2024

Oct 29, 2024

Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry - Simply Wall St

Oct 29, 2024